US Medicare Part D Inflation Is Real, MedPAC Rebate Data Show
Executive Summary
The US Medicare Payment Advisory Commission shares its first looks at the impact of rebates in the Medicare Part D program. Rebates do indeed distort the overall spending trends, the analyses suggest – but underlying prices are still increasing relatively quickly.
You may also be interested in...
A Case For Transparency: J&J Suit Targets Opaque PBM Affiliate’s Efforts To Exploit Copay Programs
Lawsuit highlights the lack of transparency into pharmacy benefit manager activities and how their programs can influence drug pricing. A Senate hearing on PBMs held shows increasing momentum behind a Federal Trade Commission study on potential anti-competitive activity in the market sector.
Medicare Part D Proposed Rule To Lower Prices Targets PBMs, Benefits Manufacturers
Proposal reflects a concern that plans and pharmacy benefit managers are inappropriately benefitting from price concessions (in this case from pharmacies) while beneficiaries are not, a theme the pharma industry has been pushing for some time.
MedPAC’s Part B Options Include ‘Value-Based’ Payment During Accelerated Approval
Medicare Payment Advisory Commission also considering reviving least costly alternative policy in some way, but remains relatively hesitant about changes to ASP+6%.